Announcing the Intent To Award a Sole-Source Supplement for the Christopher and Dana Reeve Foundation, 51679 [2022-18118]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 162 / Tuesday, August 23, 2022 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Announcing the Intent To Award a
Sole-Source Supplement for the
Christopher and Dana Reeve
Foundation
Notice of Intent to award a sole
source supplement to the Christopher
and Dana Reeve Foundation.
ACTION:
The Administration for
Community Living (ACL) is announcing
the award of a sole-source supplement
for the National Paralysis Resource
Center (PRC) as a result of the 2022
Congressional budget appropriations.
The National Paralysis Resource Center
is operated by the Christopher and Dana
Reeve Foundation and offers important
programmatic opportunities for persons
with disabilities and older adults. The
NPRC provides comprehensive
information for people living with
spinal cord injury, paralysis, and
mobility-related disabilities and their
families. Resources include information
and referral by phone and email in
multiple languages; a peer and family
support mentoring program; a military
and veterans’ program; multicultural
outreach services; multiple quality of
life grants; and a national website. The
administrative supplement for FY 2022
will be in the amount of $747,037,
bringing the total award for FY 2022 to
$9,447,037.
SUPPLEMENTARY INFORMATION:
Program Name: National Paralysis
Resource Center.
Recipient: Christopher and Dana
Reeve Foundation.
Period of Performance: The
supplement award will be issued for the
second year of a five-year project period,
July 1, 2022, through June 30, 2023.
Award Amount: $747,037.
Award Type: Cooperative Agreement.
Statutory Authority: This program is
authorized under section 317 of the
Public Health Service Act (42 U.S.C.
247(b–4)); Consolidated and Further
Continuing Appropriations Act, 2016,
Public Law 114–113 (Dec. 18, 2015).
CFDA Number: 93.325 Discretionary
Projects.
The purpose of the supplemental
funding is to support the expansion the
National Paralysis Resource Center to
improve the health and quality of life of
individuals living with paralysis and
their families by raising awareness of
and facilitating access to a broad range
of services relevant to individuals with
paralysis. With the additional funding,
the NPRC will work to expand the
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:53 Aug 22, 2022
Jkt 256001
National Resource and Information
Center; increase the health and quality
of life of Americans with disabilities
living with paralysis; increase support
and resources to people with paralysis,
their families and caregivers; expand
collaboration with federal agencies and
other national organizations that have a
vested interested in the paralysis
community; and strengthen
performance measures.
Dated: August 18, 2022.
Alison Barkoff,
Acting Administrator and Assistant Secretary
for Aging.
[FR Doc. 2022–18118 Filed 8–22–22; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–D–0447]
Charging for Investigational Drugs
Under an Investigational New Drug
Application: Questions and Answers;
Revised Draft Guidance for Industry;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a revised
draft guidance for industry entitled
‘‘Charging for Investigational Drugs
Under an IND: Questions and Answers.’’
Since issuance of the final guidance in
2016, FDA has received questions from
stakeholders through the docket and in
the form of communications with
review divisions. These questions relate
to the implementation of FDA’s
regulation on charging for
investigational drugs under an
investigational new drug application
(IND) for the purpose of either clinical
trials or expanded access for treatment
use. FDA is providing this revised draft
guidance in a question-and-answer
format, addressing the most recently
asked questions. When finalized, this
revised draft guidance will replace the
final guidance of the same title issued
in June 2016.
DATES: Submit either electronic or
written comments on the draft guidance
by October 24, 2022 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
SUMMARY:
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
51679
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2013–D–0447 for ‘‘Charging for
Investigational Drugs Under an IND:
Questions and Answers.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
E:\FR\FM\23AUN1.SGM
23AUN1
]]>Agencies
[Federal Register Volume 87, Number 162 (Tuesday, August 23, 2022)]
[Notices]
[Page 51679]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-18118]
[[Page 51679]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Community Living
Announcing the Intent To Award a Sole-Source Supplement for the
Christopher and Dana Reeve Foundation
ACTION: Notice of Intent to award a sole source supplement to the
Christopher and Dana Reeve Foundation.
-----------------------------------------------------------------------
SUMMARY: The Administration for Community Living (ACL) is announcing
the award of a sole-source supplement for the National Paralysis
Resource Center (PRC) as a result of the 2022 Congressional budget
appropriations. The National Paralysis Resource Center is operated by
the Christopher and Dana Reeve Foundation and offers important
programmatic opportunities for persons with disabilities and older
adults. The NPRC provides comprehensive information for people living
with spinal cord injury, paralysis, and mobility-related disabilities
and their families. Resources include information and referral by phone
and email in multiple languages; a peer and family support mentoring
program; a military and veterans' program; multicultural outreach
services; multiple quality of life grants; and a national website. The
administrative supplement for FY 2022 will be in the amount of
$747,037, bringing the total award for FY 2022 to $9,447,037.
SUPPLEMENTARY INFORMATION:
Program Name: National Paralysis Resource Center.
Recipient: Christopher and Dana Reeve Foundation.
Period of Performance: The supplement award will be issued for the
second year of a five-year project period, July 1, 2022, through June
30, 2023.
Award Amount: $747,037.
Award Type: Cooperative Agreement.
Statutory Authority: This program is authorized under section 317
of the Public Health Service Act (42 U.S.C. 247(b-4)); Consolidated and
Further Continuing Appropriations Act, 2016, Public Law 114-113 (Dec.
18, 2015).
CFDA Number: 93.325 Discretionary Projects.
The purpose of the supplemental funding is to support the expansion
the National Paralysis Resource Center to improve the health and
quality of life of individuals living with paralysis and their families
by raising awareness of and facilitating access to a broad range of
services relevant to individuals with paralysis. With the additional
funding, the NPRC will work to expand the National Resource and
Information Center; increase the health and quality of life of
Americans with disabilities living with paralysis; increase support and
resources to people with paralysis, their families and caregivers;
expand collaboration with federal agencies and other national
organizations that have a vested interested in the paralysis community;
and strengthen performance measures.
Dated: August 18, 2022.
Alison Barkoff,
Acting Administrator and Assistant Secretary for Aging.
[FR Doc. 2022-18118 Filed 8-22-22; 8:45 am]
BILLING CODE 4154-01-P
